Cargando…
Challenging issues in molecular-targeted therapy
There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697511/ https://www.ncbi.nlm.nih.gov/pubmed/19436605 |
_version_ | 1782168331374034944 |
---|---|
author | Ezziane, Zoheir |
author_facet | Ezziane, Zoheir |
author_sort | Ezziane, Zoheir |
collection | PubMed |
description | There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways. This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies. |
format | Text |
id | pubmed-2697511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26975112009-06-17 Challenging issues in molecular-targeted therapy Ezziane, Zoheir Ther Clin Risk Manag Short Report There are variety of anticancer treatments including chemotherapeutic drugs, which are known to induce cell growth arrest and apoptosis through DNA damage and cytoskeleton toxicity. Meanwhile, histone deacetylase (HDAC) inhibitors could apply their antitumor activity through chromatin remodeling and gene expression modulation that affect the cell cycle and survival pathways. This paper proposes an anticancer three-drug compound and discusses several challenging issues in relation to designing multidrug compounds that could possibly lead to molecular-targeted therapies. Dove Medical Press 2009 2009-03-26 /pmc/articles/PMC2697511/ /pubmed/19436605 Text en © 2009 Ezziane, publisher and licensee Dove Medical Press Ltd. |
spellingShingle | Short Report Ezziane, Zoheir Challenging issues in molecular-targeted therapy |
title | Challenging issues in molecular-targeted therapy |
title_full | Challenging issues in molecular-targeted therapy |
title_fullStr | Challenging issues in molecular-targeted therapy |
title_full_unstemmed | Challenging issues in molecular-targeted therapy |
title_short | Challenging issues in molecular-targeted therapy |
title_sort | challenging issues in molecular-targeted therapy |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697511/ https://www.ncbi.nlm.nih.gov/pubmed/19436605 |
work_keys_str_mv | AT ezzianezoheir challengingissuesinmoleculartargetedtherapy |